Search Results - "Mulot, C."

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients by Taieb, J, Balogoun, R, Le Malicot, K, Tabernero, J, Mini, E, Folprecht, G, Van Laethem, J-L, Emile, J-F, Mulot, C, Fratté, S, Levaché, C-B, Saban-Roche, L, Thaler, J, Petersen, L N, Bridgewater, J, Perkins, G, Lepage, C, Van Cutsem, E, Zaanan, A, Laurent-Puig, P

“…RAS mutations have been shown to confer resistance to anti- epidermal growth factor receptor (EGFR) treatment. We analysed the results of the PETACC8 trial…”
Get full text

miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial by Gaston Mathe, Y, Martin-Lannerée, S, Vazart, C, Fontaine, K, Mulot, C, Caumont, A, Montestruc, F, Le Malicot, K, Lepage, C, Taieb, J, Laurent-Puig, P

Get full text

A “chamber of errors” adaptation to assess pharmaceutical assistants’ knowledge in chemotherapy preparation by Loboda, C, Vigneron, J, Mulot, C, May, I, Demore, B

“…French preparation guidelines state that pharmacy staff who manipulate cytotoxic drugs have to follow specific training. In order to assess the pharmaceutical…”
Get full text

Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes by MOREAU, C., PAUTAS, E., GOUIN‐THIBAULT, I., GOLMARD, J.‐L., MAHÉ, I., MULOT, C., LORIOT, M.‐A., SIGURET, V.

“…Background: Initiating warfarin is challenging in frail elderly patients because of low‐dose requirements and interindividual variability. Objectives: We…”
Get full text

UDP-glucuronosyltransferase UGT1A7 genetic polymorphisms in hepatocellular carcinoma: a differential impact according to seropositivity of HBV or HCV markers? by Stücker, I, Loriot, M A, N'koutchou, G, Cénée, S, Bodin, L, Mulot, C, Gelu-Simeon, M, Pelletier, L, Bronowicki, J P, Degos, F, Beaune, P, Laurent-Puig, P, Hémon, D, Trinchet, J C, Pelletier, G

“…We conducted a case-control study to evaluate the role of UDP-glucuronosyltransferase 1A7 (UGT1A7) polymorphisms in the onset of hepatocellular carcinoma…”
Get full text

321P A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial by Gallois, C., Sroussi, M., Mouillet-Richard, S., Mulot, C., Dourthe, L.M., Mazard, T., Jary, M., de la Fouchardiere, C., Lecaille, C., Lahlou, W., Tabernero, J., van Laethem, J-L., Lepage, C., Emile, J.F., Taieb, J., de Reynies, A., Laurent-Puig, P.

Get full text

3018 POSTER Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/Oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000–05 trial by Boige, V, Castaing, M, Loriot, M.A, Barrois, M, Miran, I, Mulot, C, Pignon, J.P, Ducreux, M, Laurent-Puig, P

Get full text

A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency by Le Naour, Julie, Liu, Peng, Zhao, Liwei, Adjemian, Sandy, Sztupinszki, Zsofia, Taieb, Julien, Mulot, Claire, Silvin, Aymeric, Dutertre, Charles-Antoine, Ginhoux, Florent, Sauvat, Allan, Cerrato, Giulia, Castoldi, Francesca, Martins, Isabelle, Stoll, Gautier, Paillet, Juliette, Mangane, Khady, Richter, Cornelia, Kepp, Oliver, Maiuri, Maria Chiara, Pietrocola, Federico, Vandenabeele, Peter, André, Fabrice, Delaloge, Suzette, Szallasi, Zoltan, Laurent-Puig, Pierre, Zucman-Rossi, Jessica, Zitvogel, Laurence, Pol, Jonathan G, Vacchelli, Erika, Kroemer, Guido

“…For anthracycline-based chemotherapy to be immunogenic, dying cancer cells must release annexin A1 (ANXA1) that subsequently interacts with the pattern…”
Get more information

521PmiR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial by Gaston Mathe, Y, Martin-Lannerée, S, Vazart, C, Fontaine, K, Mulot, C, Caumont, A, Montestruc, F, Le Malicot, K, Lepage, C, Taieb, J, Laurent-Puig, P

Get full text

Genetic and transcriptomic analyses of early-onset colon cancer (EOCC): a post hoc analysis of 2973 patients from two adjuvant randomized trials by Gandini, A., Gallois, C., Blons, H., Mulot, C., Agueeff, N., Lepage, C., Guimbaud, R., Mineur, L., Desramé, J., Chibaudel, B., de Reyniès, A., André, T., Laurent-Puig, P., Taieb, J.

Get full text

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration by Taieb, J., Taly, V., Vernerey, D., Bourreau, C., Bennouna, J., Faroux, R., Desrame, J., Bouche, O., Borg, C., Egreteau, J., Mineur, L., Lepere, C., Deplanque, G., Mulot, C., Louvet, C., Mabro, M., Ychou, M., de Gramont, A., Andre, T., Laurent-Puig, P.

Get full text

LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration by Taieb, J, Taly, V, Vernerey, D, Bourreau, C, Bennouna, J, Faroux, R, Desrame, J, Bouche, O, Borg, C, Egreteau, J, Mineur, L, Lepere, C, Deplanque, G, Mulot, C, Louvet, C, Mabro, M, Ychou, M, de Gramont, A, Andre, T, Laurent-Puig, P

“…Abstract Background ctDNA has been recently suggested as a major prognostic factor in resected stage II and III colon cancer patients (pts)1,2. Its predictive…”
Get full text

LBA30_PR - Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration by Taieb, J., Taly, V., Vernerey, D., Bourreau, C., Bennouna, J., Faroux, R., Desrame, J., Bouche, O., Borg, C., Egreteau, J., Mineur, L., Lepere, C., Deplanque, G., Mulot, C., Louvet, C., Mabro, M., Ychou, M., de Gramont, A., Andre, T., Laurent-Puig, P.

“…ctDNA has been recently suggested as a major prognostic factor in resected stage II and III colon cancer patients (pts)1,2. Its predictive value for adjuvant…”
Get full text

Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy by Gallois, C., Taieb, J., Le Corre, D., Le Malicot, K., Tabernero, J., Mulot, C., Seitz, J.-F., Aparicio, T., Folprecht, G., Lepage, C., Mini, E., Van Laethem, J.-L., Emile, J.F., Laurent-Puig, P.

Get full text

Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients by Taieb, J., Balogoun, R., Le Malicot, K., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J.-L., Emile, J.-F., Mulot, C., Fratté, S., Levaché, C.-B., Saban-Roche, L., Thaler, J., Petersen, L.N., Bridgewater, J., Perkins, G., Lepage, C., Van Cutsem, E., Zaanan, A., Laurent-Puig, P.

“…RAS mutations have been shown to confer resistance to anti- epidermal growth factor receptor (EGFR) treatment. We analysed the results of the PETACC8 trial…”
Get full text

Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial by Taieb, J., Le Malicot, K., Balogoum, R., Tabernero, J., Mini, E., Folprecht, G., van Laethem, J.-L., Emile, J.-F., Mulot, C., Fratté, S., Levaché, C.-B., Saban-Roche, L., Thaler, J., Petersen, L. Nørgård, Sanchez, E., Bridgewater, J., Perkins, G., Lepage, C., Zaanan, A., Laurent-Puig, P.

Get full text

A retrospective of 18 years of hazelnut phenology in southwestern France by Toillon, J., Mulot-Greffeuille, C., Paradinas, A., Lefrançois, A., Ramade, L., Thomas, M.

Get full text

Collection of human genomic DNA from buccal cells for genetics studies: comparison between cytobrush, mouthwash, and treated card by Mulot, Claire, Stücker, Isabelle, Clavel, Jacqueline, Beaune, Philippe, Loriot, Marie-Anne

“…Alternative sources such as buccal cells have already been tested for genetic studies and epidemiological investigations. Thirty-seven volunteers participated…”
Get full text

Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000–05 trial by Castaing, M., Loriot, M. A., Barrois, M., Miran, I., Mulot, C., Laurent-Puig, P., Pignon, J. P., Ducreux, M., Boige, V.

“…Abstract only 2508 Background: The FFCD 2000–05 randomized trial compared simplified LV5FU2 followed by FOLFOX6 (arm 1) to FOLFOX6 followed by FOLFIRI (arm 2)…”
Get full text

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05 by Boige, V., Mendiboure, J., Jp, Pignon, Ma, Loriot, Castaing, M., Barrois, M., Malka, D., Da, Trégouët, Bouché, O., Corre D, Le, Miran, I., Mulot, C., Ducreux, M., Beaune, P., Laurent-Puig, P.

Get full text